PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2012-04-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 273
- Registration Number
- NCT00663052
- Locations
- πΉπ
Pfizer Investigational Site, Bangkok, Thailand
A Randomized, Double-Blind Study of the Efficacy and Safety of Valdecoxib Compared to Placebo for Treatment of Post- Cholecystectomy Surgery Pain
Phase 3
Completed
- Conditions
- Laparoscopic CholecystectomyPain
- Interventions
- Drug: placebo
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2008-04-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 490
- Registration Number
- NCT00661635
- Locations
- πΊπΈ
Pfizer Investigational Site, Madison, Wisconsin, United States
A Single Dose Study Investigating the Absorption and Elimination as Well as the Tolerability of Varenicline Transdermal Delivery System (e.g., a Patch) as Compared to Oral Varenicline in Adult Smokers.
Phase 1
Completed
- Conditions
- Smoking Cessation
- Interventions
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT00661765
- Locations
- πΊπΈ
Pfizer Investigational Site, Fargo, North Dakota, United States
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 487
- Registration Number
- NCT00661661
- Locations
- π―π΅
Chiba-ken Saiseikai Narashino Hospital, Narashino, Chiba, Japan
π―π΅National hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan
π―π΅Nagoya University Hospital, Nagoya, Aichi, Japan
A Multicenter, Open Label Trial To Evaluate Pain Relief With Intravenous Followed By Oral Therapy With Parecoxib/Valdecoxib 40 Mg/Day For Treatment Of Post-Laparoscopic Surgery Pain
Phase 4
Terminated
- Conditions
- Pain, Post Surgical
- Interventions
- Drug: parecoxib/valdecoxib
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2008-04-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4
- Registration Number
- NCT00660855
- Locations
- π¦π·
Pfizer Investigational Site, Buenos Aires, Argentina
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 178
- Registration Number
- NCT00658359
- Locations
- πΊπΈ
Cedars-Sinai Medical Center, Los Angeles, California, United States
πΊπΈRonald Reagan UCLA Medical Center, Los Angeles, California, United States
πΊπΈUCLA Medical Center, Los Angeles, California, United States
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
Phase 3
Terminated
- Conditions
- Generalized Anxiety Disorder
- Interventions
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2012-11-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 286
- Registration Number
- NCT00658762
- Locations
- ππΊ
Pfizer Investigational Site, Budapest, Hungary
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
Phase 3
Terminated
- Conditions
- Generalized Anxiety Disorder
- Interventions
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2012-11-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 360
- Registration Number
- NCT00658372
- Locations
- π¨π³
Pfizer Investigational Site, Tainan, Taiwan
Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 153
- Registration Number
- NCT00658684
- Locations
- π―π΅
Pfizer Investigational Site, Shibuya-ku, Tokyo, Japan
Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 251
- Registration Number
- NCT00658879
Β© Copyright 2025. All Rights Reserved by MedPath